Wave Life Sciences Ltd. is a biotechnology company focused on unlocking the broad potential of ribonucleic acid (RNA) medicines to transform human health. The Company’s RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. The Company’s diversified pipeline includes clinical programs in alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington’s disease, as well as several preclinical programs utilizing the Company’s broad RNA therapeutics toolkit. Its programs include WVE-006, SERPINA1 (AATD); WVE-007 (GalNAc), INHBE (Obesity); WVE-N531, Exon 53 (DMD), and WVE-003, mHTT (HD).
Growing
The company is in a growing phase, with the latest annual income totaling USD 42.73M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 42.73M.
Overvalued
The company’s latest PE is -5.23, at a high 3-year percentile range.
Held by Lee Ainslie
Star Investor Lee Ainslie holds 11.62M shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.15.